Insider trade

Officer sold ~$5.28M of JNJ shares in the open market

Traded Feb 17, 2026 · Filed Feb 19, 2026

Johnson & JohnsonJNJ

~$5.28M
Reported value · 22K sh @ $243.00: 13K
Holds after · shares reported: +6.3%
stock since the trade · S&P 500 +11.9%, $243.33 → $258.66 on Oct 1

Why it stands out

Johnson & Johnson's Innovative Medicine, R&D sold $5.28M of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 17, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 19, 2026

Officer$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$5,278,203

Shares × reported transaction price

Timing vs results

27 days after results of Jan 21, 2026, 56 days before results of Apr 14, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $243.33 on Feb 17, 2026, within 1% of its 52-week high, after a 17% rise over the previous 30 trading days

52-week range $146.36 (May 14, 2025) to $244.55 (Feb 12, 2026), 99% of the way up, from 251 adjusted closes. 30 trading days earlier: $207.35 on Jan 2, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Rybrevant Faspro on Feb 13, 2026, 4 days before this trade.

Biologic approved. Active ingredient: Amivantamab and Hyaluronidase-Lpuj. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-1.4%	+0.7%	-2.1%
30 days	-4.7%	-4.3%	-0.4%
90 days	-7.1%	+8.3%	-15.4%
180 days	+9.8%	+12.1%	-2.3%

Past results only. Not a forecast.

Source receipt

Record ID: 0000200406-26-000039
Filed / recorded: Feb 19, 2026, 2:12 AM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: JOHNSON & JOHNSON
Issuer CIK: 200406
Ticker: JNJ
Reporting person: John C Reed
Relationship: Officer
Officer title: EVP, Innovative Medicine, R&D
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Feb 17, 2026
Transaction code: S
Shares / units: 21,721
Price per share: $243.00
Acquired / disposed: Disposed (D)
Shares owned after: 12,941
Ownership form: Direct
Amendment: No

Around the same time

Veterans Affairs awarded7mo ago

$20Kcommitted so far

Balversa 4 mg

Starts Mar 20, 2026Ended Mar 24, 2026

The Department of Veterans Affairs has already agreed to pay Johnson & Johnson $20K. The job runs until Mar 24, 2026.

Why it stands out Official record

7mo ago

75.26Derivative units · @ $166.10

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

7mo ago

206.49Derivative units · @ $242.14

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

Why it stands out

Dates, kept separate

Context

After it was reported

Source receipt

Around the same time

$20Kcommitted so far

75.26Derivative units · @ $166.10

206.49Derivative units · @ $242.14

Most active this month